- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06232070
Real World Evaluation of Lunit INSIGHT MMG Technology
Real World Evaluation of Lunit INSIGHT MMG Technology in a Population of Women With Breast Symptoms Referred to a "One-stop" Breast Clinic
This study is a single-centre prospective observational cohort study designed to assess and compare the sensitivity and specificity of a Lunit INSIGHT MMG assisted human reading to the standard care double human reading process within mammography review at a "one-stop" breast clinic (non-inferiority study).
The current imaging reporting process is a sequential double read of mammography and ultrasound (if available) images, by consultant radiologists or radiographers. The first reader produces a report which is then sent to the second reader who reviews it. If the second reader agrees with the first, this is reflected in the second reader's report which translates into a decision for further action; in the event of disagreement, a third reader arbitrates and produces the final report.
In the past, breast clinics have had to resort to single reader reporting due to staff shortages and high demand. This results in delays to any further assessments that may be required. It is worth noting however that despite difficulties in meeting the target, the current clinical pathway has proven to be cost effective.
The Lunit INSIGHT MMG tool could generate benefits and potential efficiencies if it were introduced to the clinical service as an assistant reader within the mammography reporting process, by replacing one of the two human readers in the current standard of care. Before this can be assessed however, its non-inferiority in combination with a human reader in comparison to standard of care (double human reading) must first be established. This study will aim to address this issue in the first instance, maintaining standard of care for all patients seen within the 2 week wait pathway, by introducing the use of Lunit INSIGHT MMG into one of two arms within this prospective, observational parallel cohort study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study has three main objectives, which will be met through separate sub-studies and analyses.
First, it will investigate and compare the performance of the Lunit INSIGHT MMG tool in combination with a human reader, against the current standard of care (two human readers). Quantitative data will be collected from a prospective, observational cohort study which will take place during routine clinical care at the participating site in parallel to standard care. The main aims will be:
- To assess and compare the sensitivity and specificity of Lunit INSIGHT MMG combined with a single human reader for non-inferiority compared to double human reading
- To assess and compare the rate of escalation to arbitration (following non-agreement) for non-inferiority of Lunit INSIGHT MMG combined with a single human reader against double human reading
- To assess clinician reported agreement with the Lunit INSIGHT MMG report
- To address any differences in performance characteristics as a function of patient age 6 To assess how Lunit score relates to tumour grade on biopsy
Second, the acceptability and perceptions surrounding the AI will be investigated using qualitative data obtained from patient and workforce interviews and questionnaires from the latter. The main aims will be to assess the acceptability of the Lunit INSIGHT MMG tool to patients and the workforce and explore patient and workforce perceptions surrounding it and its implementation in clinical pathways.
Third, a health economic evaluation will be carried out in a cost effectiveness analysis to assess the value of introducing the Lunit INSIGHT MMG tool at a "one-stop" breast clinic. The main aims will be two. The implementation costs of the Lunit Insight MMG tool and costs of a scan read by it, in combination with a human reader, will be compared against the cost of double human readings based on standard practices. In addition, a valuation of outcomes will also be undertaken following the lifetime of the cohort with the use of the Lunit INSIGHT MMG tool compared with standard of care.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Mohammad MS Sayeem
- Phone Number: +44 (0) 20 784 89527
- Email: kitec@kcl.ac.uk
Study Contact Backup
- Name: Sarah Hammoudi
- Phone Number: +44 (0) 20 784 89527
- Email: kitec@kcl.ac.uk
Study Locations
-
-
-
Leeds, United Kingdom
- The Leeds Teaching Hospitals NHS Trust
-
Principal Investigator:
- Nisha Sharma
-
Contact:
- Dr Nisha Sharma
- Email: leedsth-tr.breastscreeningresearch@nhs.net
-
Contact:
- Aneesha Qadeer
- Email: leedsth-tr.breastscreeningresearch@nhs.net
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Non-Inferiority Study
- Women 18 years of age or older.
- Referred to a "one-stop" breast clinic following GP appointment for breast symptoms.
Patient and workforce qualitative studies Patients: as above. Workforce: Clinical staff and other key stakeholders involved in the implementation of Lunit INSIGHT MMG both male and female
• Able to undergo mammography.
Exclusion Criteria:
Non-Inferiority Study
- Men will not be included in this study.
- Women who are not able to tolerate a mammogram or are unable to have one due to physical difficulties in engagement with the technology caused by immobility or being wheelchair bound.
Patient and workforce qualitative studies Patients: as above. Workforce: Has no connection to Lunit INSIGHT MMG implementation irrespective of being male or female
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Standard Pathway Arm
All participating patients will have their mammograms reported using the standard of care.
The mammograms randomised to the Standard Pathway arm will be reported using the current standard of care, which involves two human readers; The readers will be blind to Lunit INSIGHT MMG report
|
|
Lunit Assisted Arm
All participating patients will have their mammograms reported using the standard of care.
Those randomised to the Lunit assisted arm will also undergo double reader process , ensuring the current standard of clinical care is provided.
In addition to that, the Lunit INSIGHT MMG report will also be available to the readers.
Within this arm, each reader will be presented with a Likert scale to rank their level of agreement with the Lunit INSIGHT MMG report
|
In the Lunit Assisted arm, the radiographers will also be seeing the Lunit INSIGHT MMG reports while reading the mammograms.
The standard of care will be followed in all the cases
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity, specificity and cost effectiveness of Lunit INSIGHT MMG
Time Frame: Jan-Nov 2024
|
To assess and compare the sensitivity and specificity (further follow up or not) of Lunit INSIGHT MMG combined with a single human reader for non-inferiority against double human reading
|
Jan-Nov 2024
|
Acceptability of Lunit INSIGHT MMG to patients and NHS workforce
Time Frame: Jan-Nov 2024
|
To assess the acceptability of Lunit INSIGHT MMG to patients and NHS workforce.
This will be done through a patient and workforce qualitative study involving in-depth interviews and questionnaires
|
Jan-Nov 2024
|
Cost Effectiveness of introducing Lunit INSIGHT MMG
Time Frame: Jan-Nov 2024
|
To assess the cost effectiveness of introducing Lunit INSIGHT MMG at the 'one-stop' breast clinic
|
Jan-Nov 2024
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity and specificity of the Lunit INSIGHT MMG assisted single Human reading compared to double human reading
Time Frame: Jan-Nov 2024
|
The sensitivity and specificity of the Lunit INSIGHT MMG assisted single human reading will be compared to double human reading through ROC curve comparison
|
Jan-Nov 2024
|
Number and proportion of non-agreement/arbitrations in the Lunit INSIGHT MMG assisted arm vs the Standard of care pathway arm
Time Frame: Jan-Nov 2024
|
Chi squared and Wilson tests on the number and proportion of non-agreement/arbitration in the Lunit INSIGHT MMG assisted arm vs the Standard of Care pathway arm
|
Jan-Nov 2024
|
Correlation between the Lunit INSIGHT MMG abnormality score and the level of confidence of human reader 1 in the Lunit result
Time Frame: Jan-Nov 2024
|
Correlation between Lunit INSIGHT MMG abnormality score (percentage continuous) and the level of confidence of human reader 1 in the Lunit result as measured by Likert scale
|
Jan-Nov 2024
|
Correlation of reader level of concern score
Time Frame: Jan-Nov 2024
|
Correlation of reader level of concern score (categorical ordinal) with Lunit INSIGHT MMG abnormality score (percentage continuous).
This can be done using tests Kendall's tau or Somers' D if the abnormality percentage are converted to categorical scores
|
Jan-Nov 2024
|
Investigation of performance of the Lunit assisted arm in sub-categories of patients
Time Frame: Jan-Nov 2024
|
Investigation of performance of the Lunit assisted arm in sub-categories of patients for different ages, breast density, BMI, smoking status and family history using ANOVA or Kruskal-Wallis tests
|
Jan-Nov 2024
|
Comparison of time to final report between the two arms
Time Frame: Jan-Nov 2024
|
Comparison of time to final report between the two arms with T-test and Mann-Whitney test.
|
Jan-Nov 2024
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nisha Sharma, The Leeds Teaching Hospital NHS Trust
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Lunit INSIGHT protocol
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
Clinical Trials on Lunit INSIGHT MMG
-
Karolinska University HospitalKarolinska Institutet; Lunit Inc.; Capio Sankt Görans HospitalActive, not recruitingBreast Neoplasm FemaleSweden
-
Kyung Hee University Hospital at GangdongKorea Health Industry Development InstituteActive, not recruitingBreast CancerKorea, Republic of
-
H. Francis FarhadiDePuy SynthesRecruiting
-
Washington University School of MedicineMayo ClinicCompletedCubital Tunnel Syndrome | Peroneal Nerve EntrapmentUnited States
-
DascenaNot yet recruitingSepsis | Septic Shock | Severe Sepsis
-
Suez Canal UniversityDalian Medical UniversityCompletedNeuromuscular BlockadeBosnia and Herzegovina, China
-
Moravian UniversityCompleted
-
DascenaUniversity of California, San FranciscoWithdrawnSepsis | Septic Shock | Severe Sepsis
-
EyeQue Corp.Eye Boutique OptometryCompletedVisual AcuityUnited States